---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034162"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:58:56.343808+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences reports FY2025 net loss of $39.7M; Phase 1b fully enrolled, $75.5M financing closed

## Summary
- Net loss of $39.7M in FY2025; R&D expense soared to $33.4M from $10.6M a year ago, driven by PRECISE-AD trial.
- Cash of $6.1M at Dec 31, 2025; subsequent $75.5M private placement in Feb 2026 provides cash runway through 2027.
- PRECISE-AD Phase 1b enrollment completed with 144 patients; six-month blinded interim data expected early Q3 2026.
- PMN310 continues to show favorable safety profile with no treatment-related SAEs reported after over 12 months of dosing.
- PMN310 granted FDA Fast Track Designation in July 2025; goal to advance directly into a single registrational study.

## SEC filing metadata
- accession: 0001104659-26-034162
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/0001104659-26-034162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034162
- JSON: https://secwatch.observer/filing/0001104659-26-034162.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034162.txt

## Key facts
- Earnings Releases
  ProMIS Neurosciences Inc. reported the year ended December 31, 2025 results: net income $39.7 million.
  - Period: the year ended December 31, 2025
  - Net income: $39.7 million
  - Result: reported results
  source text: For the year ended December 31, 2025, the Company reported a net loss of $39.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/0001104659-26-034162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.